Ion Beam ApplicationsIOBCF +0.51%82 Return-on-Tangible-Equity is 34.54% as of Dec. 2025, which is 416% above its 10-year median of 6.69. GuruFocus rates IOBCF with a GF Score™ of 82/100 and a GF Value™ of $18.71 (Fairly Valued). The stock has 10 warning signs investors should review. Among 760 Medical Devices & Instruments companies, Ion Beam Applications ranks better than 75.39% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Ion Beam Applications's annualized net income for the quarter that ended in Dec. 2025 was $35.8 Mil. Ion Beam Applications's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $103.6 Mil. Therefore, Ion Beam Applications's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 34.54%.
The historical rank and industry rank for Ion Beam Applications's Return-on-Tangible-Equity or its related term are showing as below:
IOBCF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -34.23 Med: 6.69 Max: 27.21
Current: 14.48
During the past 13 years, Ion Beam Applications's highest Return-on-Tangible-Equity was 27.21%. The lowest was -34.23%. And the median was 6.69%.
IOBCF's Return-on-Tangible-Equity is ranked better than 75.39% of 760
companies
in the Medical Devices & Instruments industry
Industry Median: 4.115
vs IOBCF: 14.48
Ion Beam Applications (OTCPK:IOBCF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Ion Beam Applications Return-on-Tangible-Equity Related Terms
Ion Beam Applications Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Ion Beam Applications's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ion Beam Applications Return-on-Tangible-Equity Chart
IOBCF vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Ion Beam Applications's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ion Beam Applications Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ion Beam Applications's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Ion Beam Applications's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 34.54% mean?
Ion Beam Applications (IOBCF) has a Return-on-Tangible-Equity of 34.54% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Ion Beam Applications and its competitors. This is 416% above median its historical median of 6.69. According to the industry distribution chart, Ion Beam Applications ranks #187 out of 760 companies in the Medical Devices & Instruments industry, placing it in the top 24.6%.
Is Ion Beam Applications' Return-on-Tangible-Equity too high?
Ion Beam Applications' current Return-on-Tangible-Equity of 34.54% is 416% above median its 10-year median of 6.69. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.12. Ion Beam Applications' value of 34.54% is 739.4% above this industry median. Based on the distribution chart, Ion Beam Applications ranks #187 out of 760 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Ion Beam Applications has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ion Beam Applications' Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Ion Beam Applications ranks #187 out of 760 companies for Return-on-Tangible-Equity. This places Ion Beam Applications in the top 25% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.12. Ion Beam Applications' value of 34.54% is 739.4% above this benchmark. While the company's 10-year median is 6.69 vs. the industry median of 4.12, Ion Beam Applications has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.12, based on 760 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ion Beam Applications's current Return-on-Tangible-Equity of 34.54% is 739.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Ion Beam Applications and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ion Beam Applications's current Return-on-Tangible-Equity is 34.54%, which is 416% above median its own 10-year median of 6.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ion Beam Applications stock overvalued right now?
Based on GuruFocus' analysis, Ion Beam Applications (IOBCF) is currently considered Fairly Valued. The stock's GF Value™ is $18.71, compared to a current price of $19.00 — trading 1.5% above its estimated fair value. The current Return-on-Tangible-Equity is 34.54%, which is 416% above median its 10-year median of 6.69 and 739.4% above the Medical Devices & Instruments industry median of 4.12. Ion Beam Applications' overall GF Score™ is 82/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Ion Beam Applications (IOBCF), the current Return-on-Tangible-Equity is 34.54% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ion Beam Applications (IOBCF) Overvalued in 2026?
Based on GuruFocus' analysis, Ion Beam Applications stock appears to be overvalued.
The current stock price of $19.00 is trading 1.5% above its estimated GF Value™ of $18.71.
GuruFocus considers Ion Beam Applications to be Fairly Valued.
Key valuation signals for IOBCF:
Return-on-Tangible-Equity: 34.54% (416% above median its 10-year median of 6.69)
GF Value™: $18.71 vs. price of $19.00 (1.5% above fair value)
Industry Position: 739.4% above the Medical Devices & Instruments median (#187 of 760)
No single metric tells the full story. See the IOBCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ion Beam Applications SA develops and manufactures medical devices and software solutions. The firm operates in three segments: IBA Clinical, including Proton Therapy and Dosimetry; IBA Technologies; and IBA Corporate. Proton therapy and other accelerators contribute to the majority of sales. It offers solutions for precision cancer treatment through the use of proton beams, as well as cyclotrons used for the production of radioisotopes and industrial accelerators for sterilization and ionization. The dosimetry business sells measurement and quality assurance instruments for radiotherapy and medical imaging. The firm operates in three geographical areas: Belgium, the United States, China, Germany, and India.
82GF Score
Get the complete analysis for IOBCF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IOBCF has been successfully added to your 
